Ofatumumab Based Chemoimmunotherapy (CIT) for Patients with Previously Untreated CLL

被引：0
|
作者：
Shanafelt, Tait D. [1 ]
Lanasa, Mark C. [2 ]
Zent, Clive S. [1 ]
Leis, Jose F. [3 ]
Call, Timothy G. [1 ]
LaPlant, Betsy R.
Tun, Han [4 ]
Bowen, Deborah A. [1 ]
Jelinek, Diane F. [5 ]
Hanson, Curtis A. [6 ]
Kay, Neil [1 ]
机构：
[1] Mayo Clin, Div Hematol, Rochester, MN USA
[2] Duke Univ, Med Ctr, Durham, NC USA
[3] Mayo Clin Arizona, Div Hematol & Med Oncol, Scottsdale, AZ USA
[4] Mayo Clin Jacksonville, Jacksonville, FL 32224 USA
[5] Mayo Clin, Dept Immunol, Rochester, MN USA
[6] Mayo Clin, Div Hematopathol, Dept Lab Med, Rochester, MN USA
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1665 / 1666
页数：2
相关论文
共 50 条
  • [21] Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia
    Wierda, William G.
    Kipps, Thomas J.
    Duerig, Jan
    Griskevicius, Laimonas
    Stilgenbauer, Stephan
    Mayer, Jiri
    Smolej, Lukas
    Hess, Georg
    Griniute, Rasa
    Hernandez-Ilizaliturri, Francisco J.
    Padmanabhan, Swaminathan
    Gorczyca, Michele
    Chang, Chai-Ni
    Chan, Geoffrey
    Gupta, Ira
    Nielsen, Tina G.
    Russell, Charlotte A.
    BLOOD, 2011, 117 (24) : 6450 - 6458
  • [22] A phase II trial of alemtizimab and rituximab in patients with previously untreated CLL
    Frankfurt, Olga
    Hamilton, Elizabeth
    Acharya, Simbi
    Duffey, Sara
    Raji, Adekunle
    Rosen, Steven T.
    BLOOD, 2007, 110 (11) : 612A - 613A
  • [23] A phase 2, multicenter study investigating ofatumumab and bendamustine combination in patients with untreated or relapsed CLL
    Flinn, Ian W.
    Panayiotidis, Panayiotis
    Afanasyev, Boris
    Janssens, Ann
    Grosicki, Sebastian
    Homenda, Wojciech
    Smolej, Lukas
    Kuliczkowski, Kazimierz
    Doubek, Michael
    Domnikova, Natalia
    West, Sarah L.
    Chang, Chai-Ni
    Barker, Alison M.
    Gupta, Ira V.
    Wright, Oliver J.
    Offner, Fritz
    AMERICAN JOURNAL OF HEMATOLOGY, 2016, 91 (09) : 900 - 906
  • [24] PROLONGing PFS with ofatumumab in patients with CLL
    Lisa Hutchinson
    Nature Reviews Clinical Oncology, 2015, 12 : 622 - 622
  • [25] A PHASE II MULTI-CENTER TRIAL OF PENTOSTATIN PLUS CYCLOPHOSPHAMIDE WITH OFATUMUMAB (PCO) IN OLDER PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS
    Montillo, M.
    Rossi, D.
    Motta, M.
    Quaresmini, G.
    Rossi, M.
    Coscia, M.
    Anastasia, A.
    Rossini, F.
    Cortellezzi, A.
    Nador, G.
    Scarfo, L.
    Cairoli, R.
    Frustaci, A. M.
    Dal Ceggio, D.
    Picardi, P.
    De Paoli, L.
    Orlandi, E.
    Rambaldi, A.
    Morra, E.
    Massaia, M.
    Tedeschi, A.
    HAEMATOLOGICA, 2014, 99 : 61 - 62
  • [26] PROLONGing PFS with ofatumumab in patients with CLL
    Hutchinson, Lisa
    NATURE REVIEWS CLINICAL ONCOLOGY, 2015, 12 (11) : 622 - 622
  • [27] Phase II Trial of Ofatumumab (OFA) for Older Patients and Patients Who Refuse Fludarabine-Based Regimens with Previously Untreated Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
    Flinn, Ian W.
    Harwin, William N.
    Ward, Patrick
    Doss, Habib H.
    Papish, Steven W.
    Hainsworth, John D.
    Berdeja, Jesus G.
    Byrd, John C.
    BLOOD, 2012, 120 (21)
  • [28] Weighted prognostic models for survival in untreated and previously treated patients with CLL.
    Wierda, WG
    O'Brien, S
    Wang, X
    Ferrajoli, A
    Faderl, S
    Thomas, D
    Ravandi, F
    Do, K
    Kantarjian, H
    Lerner, S
    Keating, M
    BLOOD, 2005, 106 (11) : 334B - 334B
  • [29] Phase 3 Trial of Acalabrutinib in Combination with Venetoclax, With and Without Obinutuzumab Versus Chemoimmunotherapy for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
    Brown, Jennifer R.
    Eichhorst, Barbara
    Ghia, Paolo
    Kater, A. P.
    Li, Jianyong
    Khurana, Sudha
    Elhamy, Mostafa
    Wang, Min Hui
    Seymour, John F.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S221 - S222
  • [30] Risk-Adapted, Ofatumumab-Based Chemoimmunotherapy and Maintenance in Treatment-Naive CLL: A Phase II Study
    Desai, Sanjal
    Drinkwater, Dennis
    Mo, Clifton Craig
    Farooqui, Mohammed Z. H.
    Soto, Susan
    Valdez, Janet
    Gaglione, Erika M.
    Tian, Xin
    Nierman, Pia
    Lotter, Jennifer
    Marti, Gerald
    Nichols, Cydney
    Taneja, Alankrita
    Herman, Sarah E. M.
    Maric, Irina
    Wake, Laura M.
    Stetler-Stevenson, Maryalice
    Yuan, Constance M.
    Hughes, Tom
    Lindorfer, Margaret A.
    Taylor, Ronald P.
    Wiestner, Adrian
    Ahn, Inhye E.
    BLOOD, 2019, 134
12345